Introduction
============

Renal cell carcinoma is the third most frequent urological malignant neoplasms worldwide, among which, clear cell renal cell carcinoma (ccRCC) accounts for approximately 80-90% [@B1]. It is estimated that about 14,400 deaths and 63,990 new cases associated with renal cell carcinoma occur during 2017 in the U.S [@B2]. Smoking, hypertension, and obesity are proven to be the high risk of renal cell carcinoma [@B3],[@B4]. Among these, smoking increases renal cell carcinoma risk by 54% in men and by 22% in women [@B5]. Therefore, it is urgent to identify the molecular mechanism of ccRCC associated with smoking to understand the pathogenesis of smoking-related ccRCC and to find a novel biomarker for early diagnosis and treatment.

The breakthrough in sequencing of cancer genomes make great contribute to reveal the potential pathological mechanisms in various cancers [@B6].

However, few studies concentrate on the interrelated genes which may have similar function. Weighted gene co-expression network analysis (WGCNA) is a system biology approach which has been widely applied to identifying the hub genes associated with clinical features in various cancer [@B7],[@B8]. According to the gene expression profiles, WGCNA can construct a gene co-expression network and divide the co-expressed genes into different modules. After that, WGCNA can find the most related module with clinical traits and identify the most central genes among it [@B9].

In this study, we utilized WGCNA to identify hub genes of ccRCC associated with smoking, which may decipher the potential mechanisms between smoking and ccRCC.

Material and Methods
====================

Study design and collection of microarray data
----------------------------------------------

First, we designed a flow chart to understand the whole process of the study (Figure [1](#F1){ref-type="fig"}A). The raw data of GSE46699 was obtained from the Gene Expression Omnibus database (*<http://www.ncbi.nlm.nih.gov/geo/>*) and was annotated according to the Affymetrix Human Genome U133 Plus 2.0 Array platform (Affymetrix, Santa Clara, CA, USA). This dataset contained 130 samples, including 40 non-smoking normal samples, 44 non-smoking tumor samples, 23 smoking normal samples, 23 smoking tumor samples. Moreover, another two datasets GSE2109 and GSE10072 were downloaded to validate the results. The description of GSE46699, GSE2109 and GSE10072 were listed in Table [1](#T1){ref-type="table"}.

Data preprocessing
------------------

Robust Multiarray Averaging (RMA) background correction, log2 transformed and quantile normalization were sequentially utilized to process the raw expression data. Then, the \'\'affy\'\' R package and Affymetrix annotation files were used to summarize and annotate the probes respectively. Besides, sample clustering was applied to evaluate the quality of GSE46699 (Figure [1](#F1){ref-type="fig"}B). Test sets GSE2109 and GSE10072 were performed the same data preprocessing.

Screening for differentially expressed genes
--------------------------------------------

The limma R package, based on empirical Bayes methods and linear models, was used to find DEGs between smoking and non-smoking ccRCC samples. The DEGs threshold was set at a false discovery rate (FDR) \< 0.05 and \|log2 fold change (FC)\| \> 0.585 to be further analyzed.

Constructing gene co-expression network
---------------------------------------

Before we utilized the "WGCNA" package to construct the scale-free gene co-expression network [@B10],[@B11], we first verified the qualification of DEGs. Then, Pearson\'s correlation matrices were conducted and a weighted adjacency matrix were performed by a formula amn = \|cmn\|^β^ (cmn represents Pearson\'s correlation between genes, amn represents adjacency between genes, the β parameter could magnify the correlation between genes). An appropriate power of β was chosen on basis of standard scale-free networks. Subsequently, we transformed the adjacency into topological overlap matrix (TOM) [@B12] and identified modules including similar genes by hierarchically clustering genes [@B13].

Discovering module of interest
------------------------------

We first defined module eigengenes (MEs) as the most principal component and summarize all genes into a single characteristic expression profile. Then, the interested module was identified by calculating the relevance between MEs and smoking. After that, the log10 transformation of the *P* value was defined as gene significance (GS) and the average GS for all genes in the module was defined as the module significance (MS). Finally, the module with the highest MS score was chosen as the one related to smoking.

Identification and validation of hub genes
------------------------------------------

Genes in the interested module with module membership \> 0.8 and gene significance \> 0.2 were defined as hub gene. Then, we constructed protein-protein interaction (PPI) networks and screen hub nodes through mapping all genes to the Cytoscape v3.4.0 software (*<http://cytoscape.org/>*) [@B14] and the Search Tool for the Retrieval of Interacting Genes (STRING, *<http://www.string-db.org/>*) [@B15],[@B16]. To screen the most important hub gene, we performed linear regression analysis to observe the relationship between the hub gene and smoking. In orders to further validate the results, we used GSE2109 and GSE10072 datasets to check the relevance between the hub gene and smoking. Furthermore, The Gene Expression Profiling Interactive Analysis (GEPIA, *<http://gepia.cancer-pku.cn/>*) was used to validate the expression and prognosis of hub gene [@B17],[@B18].

Functional enrichment analysis
------------------------------

DEGs in the interested module were put into The Database for Annotation, Visualization and Integrated Discovery (DAVID, *<https://david.ncifcrc.gov/>*) [@B19] to obtain the enriched biological process and KEGG pathway with the cutoff criteria of *P* \< 0.05.

Gene Set Enrichment Analysis (GSEA)
-----------------------------------

According to the expression level of the hub gene, we divided 530 samples of ccRCC downloaded from TCGA into two groups. To detect whether the previously defined biological processes and KEGG pathway were enriched in the two groups, we conducted GSEA with the cutoff criteria of FDR \< 0.05 [@B20].

Ethics statement
----------------

Human ccRCC tissue samples (n=18) and human paracancerous tissues (n=18) were all collected from patients suffering renal cancer in surgery and were stored in liquid nitrogen for later RNA isolation. The study was approved by the Ethics Committee at Zhongnan Hospital of Wuhan University (approval number: 2015029). All experimental methods were carried out in accordance with the approved guidelines.

Cell culture
------------

Human ccRCC cell line 786-O was purchased from Chinese Academy of Sciences in Shanghai. 786-O was cultured in RPMI-1640 (Gibco, China) medium with 10% fetal bovine serum (FBS, Gibco, Australia) in a humidified atmosphere containing 5% CO~2~ at 37 °C.

Total RNA isolation and quantitative real time PCR (qRT-PCR)
------------------------------------------------------------

Total RNA was isolated from kidney tissues by RNeasy Mini Kit (Cat. \#74101, Qiagen, Germany). 1 µg of total RNA was used as the template to synthesize first-strand cDNA by utilizing ReverTra Ace qPCR RT Kit (Toyobo, China). All primers were conducted with iQTM SYBR® Green Supermix (Bio-Rad, China) in a final volume of 20 μl with Bio-Rad iCycler (Cat. \#CFX96).

Primer sequences of *TOP2A* (annealing temperature is 60°C): 5\'-ACCATTGCAGCCTGTAAATGA-3\' (forward); 5\'-GGGCGGAGCAAAATATGTTCC-3\' (reverse).

Primer sequences of *GAPDH* (loading control, annealing temperature is 60°C): 5\'-GGAGCGAGATCCCTCCAAAAT-3\' (forward); 5\'-GGCTGTTGTCATACTTCTCATGG-3\' (reverse).

Relative gene abundance was calculated from the ΔΔCT values as: 2^-ΔΔCT^.

Cell transfection and reagents
------------------------------

The three specific small interfering RNAs: si*TOP2A*-1: 5\'-CUCCUAACUUCUAGUAACUTT-3\'; si*TOP2A*-2: 5\'-GAUCCACCAAAGAUGUCAATT-3\'; si*TOP2A*-3: 5\'-GUCCAGUUAAACAAGAAGUTT-3\' against *TOP2A* were synthesized by Genepharma Ltd. in Suzhou, China. For transfection, Lipofectamine 2000 (Invitrogen, USA) was used as the transfection reagent according to the manufacturer\'s instructions.

MTT assay
---------

The MTT (methyl thiazolyl tetrazolium, Sigma-Aldrich, MO, USA) assay was used for cell viability measurement in ccRCC cells. After transfection for 48 h, 786-O cells were seeded in 96-well plates (3000 cells per well) in RPMI-1640 medium containing 10% FBS for 5 days. Then, 20 μl of MTT reagent was added to each well for 4 h at 37 °C. After discarding the medium, the precipitates were dissolved by 200 μl of DMSO. The absorbance was measured at 490 nm using a Spectramax M5 spectrophotometer (Molecular Devices, Sunnyvale, USA).

Colony formation assay
----------------------

After transfection for 48 h, 786-O cells were plated in 6-well plates (800 per well) and cultured for 14 days. Then, surviving colonies (\> 50 cells per colony) were fixed by 4% PFA for 30 min, stained with crystal violet and photographed.

Flow cytometry analysis for the alterations of cell cycle
---------------------------------------------------------

For cell cycle analysis, 786-O cells were harvested and washed by cold PBS for three times after transfection for 48 h. Then, the cells were resuspended with 1× DNA Staining Solution containing propidium iodide and permeabilization solution (Multisciences, China) in the dark. After incubation at 37 °C for 30 min. The sample was analyzed by flow cytometry analysis (Cat. \#FC500, Beckman, USA).

Western blot analysis
---------------------

The RIPA buffer with protease inhibitor and phosphatase inhibitor (Sigma-Aldrich, USA) was used to extract total protein of 786-O cells. We used 10% SDS-PAGE to resolve the total protein and transferred the SDS-PAGE to PVDF membrane (Millipore, USA). Then, membranes were blocked by 5% non-fat milk and incubated with primary antibodies at 4°C for overnight. After washing, secondary antibody was used to incubated the membranes at room temperature for 2 h. Bands were visualized using an enhanced chemiluminescence (ECL) kit (Bio-rad, USA) and detected by BIO-RAD ChemiDoc MP Imaging System (Bio-Rad, USA).

Western blotting was performed using the following antibodies: anti-TOP2A, 1:1000 (Proteintech); anti-CDK1, 1:1000 (Abcam); anti-CDK2, 1:1000 (Abcam ); anti-CCNA1/2, 1:2000 (Abcam); anti-p-TP53, 1:1000 (Abcam); anti-TP53, 1:1000 (Abcam). Blotting membranes were stripped and probed again with anti-GAPDH antibodies (Santa) as a loading control.

Statistical analyses
--------------------

All analyses were performed at least three times and represented data from three individual experiments. Two-tailed Student\'s t-tests were used to assess the statistical significance of differences between the groups. Statistical analyses were performed using SPSS 16.0. Statistical significance was considered as a *P* value \< 0.05.

Results
=======

Screening for differentially expressed genes (DEGs)
---------------------------------------------------

A total of 3053 overlapping DEGs were chosen for further analysis. Among these, 1736 were up-regulated and 1317 were down-regulated.

Constructing co-expression network
----------------------------------

When we set the soft threshold power β to 11 (scale-free R^2^=0.89), the link between genes in the gene network satisfied a scale-free network distribution (Figure [2](#F2){ref-type="fig"}A-D). A total of 15 co-expressed modules were identified (Figure [3](#F3){ref-type="fig"}A).

Finding module of interest
--------------------------

We applied 2 approaches to verify the relevance between each module and smoking. Consequently, the lightcyan module (r = 0.3, P = 0.01) exhibited higher MS and greater connection with smoking (Figure [3](#F3){ref-type="fig"}B-C) and was identified as the most relevant module.

Identification of hub genes
---------------------------

Seven hub genes (*PRC1, TOP2A, SMC4, RACGAP1, CENPK, PAPD4, ECT2*) were defined by module connectivity (Figure [2](#F2){ref-type="fig"}E) and eight hub genes (*PRC1, TOP2A, ZWINT, KNTC1, ASPM, PCNA, RRM2, CEP55*) were defined as hub nodes (Figure [2](#F2){ref-type="fig"}F).

Validation of hub genes
-----------------------

By conducting linear regression analysis with GSE2109, we observed that *TOP2A* was more relevant to smoking (Figure [4](#F4){ref-type="fig"}B), and we selected *TOP2A* as the hub gene. According to GEPIA database, we found *TOP2A* were more highly expressed in ccRCC samples (Figure [4](#F4){ref-type="fig"}A). Meanwhile, GSE2109 and GSE46699 showed that *TOP2A* was significantly overexpressed in smoking ccRCC than non-smoking ccRCC samples (Figure [4](#F4){ref-type="fig"}C, D). Interestingly, GSE10072 also proved the positive correlation between the expression of *TOP2A* and smoking in lung adenocarcinoma (Figure [4](#F4){ref-type="fig"}E). The*P* value of Figure [4](#F4){ref-type="fig"}E was listed in Table [2](#T2){ref-type="table"}. More convincingly, the qRT-PCR experiment revealed that *TOP2A* was obviously up-regulated in smoking ccRCC patients as well (Figure [4](#F4){ref-type="fig"}F). In addition, the survival analysis uncovered that up-regulation of *TOP2A* had an obviously shorter overall survival time and disease-free survival time (Figure [4](#F4){ref-type="fig"}G- H).

Functional Enrichment Analysis
------------------------------

Biological process (BP) in the lightcyan module was found to focus on cell cycle, cell division, mitotic cell cycle, cell cycle phase and cell cycle process (Figure [4](#F4){ref-type="fig"}I). KEGG pathway enrichment analysis showed DNA replication, cell cycle and p53 signaling pathway were significantly enriched in lightcyan module (Figure [4](#F4){ref-type="fig"}J).

Gene Set Enrichment Analysis (GSEA)
-----------------------------------

Six gene sets (cell cycle, leishmanial infection, antigen processing and presentation, autoimmune thyroid disease, viral myocarditis and p53 signaling pathway) were enriched in samples with highly expressed TOP2A by conducting GSEA (Figure [5](#F5){ref-type="fig"}).

Knockdown of *TOP2A* inhibited cell proliferation by triggered cell cycle arrest at G2 phase in ccRCC cell
----------------------------------------------------------------------------------------------------------

To explore the biological role of *TOP2A* in ccRCC, we established a model of *TOP2A* deficiency in 786-O cell line. The knockdown efficiency of the siRNAs was validated by qRT-PCR and Western blot analysis (Figure [6](#F6){ref-type="fig"}A). MTT assay revealed that downregulation of *TOP2A* inhibited the cell proliferation significantly comparing with the NC group (Figure [6](#F6){ref-type="fig"}B). This uncovered that silencing *TOP2A* inhibited the proliferative capacity of ccRCC cell. The colony formation assays demonstrated a similar conclusion (Figure [6](#F6){ref-type="fig"}C). Flow cytometry analysis also showed that knockdown of *TOP2A* triggered cell cycle arrest at G2 phase (Figure [6](#F6){ref-type="fig"}D). Indeed, cell cycle related proteins such as Cyclin A1/2 and CDK1/2 were significantly decreased in the ccRCC cell in *TOP2A* knockdown group (Figure [6](#F6){ref-type="fig"}E). Moreover, *TOP2A* deficiency strongly induced phosphorylated p53 in ccRCC cells (Figure [6](#F6){ref-type="fig"}F).

Discussion
==========

In our study, the lightcyan module associated with smoking of ccRCC was identified by applying WGCNA. Seven hub genes were obtained from the module. Then, we constructed PPI networks and found that PRC1 and *TOP2A* were both hub genes in PPI network and WGCNA. Furthermore, linear regression analyses indicated that *TOP2A* was the most correlated hub gene with the smoking ccRCC samples. The GEPIA database indicated that *TOP2A* was significantly overexpressed and resulted in poorer prognosis in ccRCC samples.

*TOP2A* encodes topoisomerase 2-alpha, an enzyme that plays a key role in the topologic states of DNA during replication and transcription, which is essential for chromosome condensation and segregation [@B21]. Our group had revealed *TOP2A* played a critical role in ccRCC carcinogenesis and progression, involving in the biological process of ccRCC proliferation [@B22],[@B23]. Meanwhile, two publications suggested that *TOP2A* is overexpressed in colorectal cancer and hepatocellular carcinoma [@B24],[@B25], and overexpression of *TOP2A* was presumed to inhibit cell proliferation in colorectal cancer [@B26]. What\'s more, several investigators have reported that *TOP2A* is an independent prognostic biomarker in various cancer, such as nasopharyngeal carcinoma, breast cancer, pancreatic cancer and renal cell carcinoma [@B27]-[@B30].

Given that a cigarette contains approximately 50 chemicals that are associated with carcinogenesis [@B31], it is not surprising that cigarette smoking is one of an etiology of renal cell carcinoma. In fact, the relationship between cigarette smoking and the development of renal cell carcinoma has been widely recognized, and previous reports demonstrated that overall survival time was significantly shorter in renal cell carcinoma patients who smoke [@B32]-[@B34].

It is noteworthy that many researchers have concentrated on elucidating the potential molecular mechanism of smoking-related lung cancer [@B35]-[@B37]. However, there is little progress in illustrating the specific underlying molecular alterations triggered by cigarette smoking in the development of ccRCC. Our study unveiled that *TOP2A* was significantly up-regulated in smoking ccRCC samples in GSE46699 and GSE2109 datasets, which was consistent with the positive correlation between *TOP2A* and smoking status in lung adenocarcinoma in GSE10072 dataset. Moreover, the result of qRT-PCR experiment revealed that *TOP2A* was significantly up-regulated in smoking ccRCC than non-smoking ccRCC samples. More importantly, *in vitro* experiments uncovered that *TOP2A* inhibited the proliferative capacity and induced cell cycle arrest at G2 phase via p53 phosphorylation.

To explain how *TOP2A* accelerated the tumorigenesis of ccRCC related to cigarette smoking, we conducted KEGG pathway enrichment analyses and GSEA. Combined with the results of the two methods, we speculated that the potential pathways influenced by *TOP2A* were cell cycle and p53 signaling pathway. It has been proved that cell cycle pathway can regulate the proliferation of colorectal cancer and lung adenocarcinoma [@B38],[@B39]. Additionally, many researchers have uncovered that p53 signaling pathway is essential to carcinogenesis, proliferation, apoptosis, and progression [@B40]-[@B42]. Interestingly, Mizuno S. *et al.* [@B43] indicated p53 signaling pathway was important for the pathogenesis of smoking-related emphysematous changes. In addition, synchronous double primary lung cancers have been reported to be induced by heavy smoking via p53 pathway [@B44]. Taken all of these evidences into account, *TOP2A* is likely to be a potential key gene in the development of smoking-related ccRCC by regulating cell cycle and p53 signaling pathway.

The major limitation of our study is lack of adequate evidence in illustrating the specific pathway of smoking-related ccRCC regulated by *TOP2A*. Further experiments in mRNA and protein levels are needed. A large-scale epidemiological survey of the relationship between smoking and ccRCC may be helpful to verify our results.

In conclusion, we used WGCNA, PPI network, GSEA and qRT-PCR to identify and validate the hub gene of ccRCC associated with cigarette smoking. *TOP2A* was identified to be a potential biomarker of ccRCC associated with cigarette smoking by regulating cell cycle signaling and p53 signaling pathway. In future, *TOP2A* may be used to assist in the diagnosis of ccRCC in smoking patients.
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![**Description of the study. (A)** Flow chart of this study. **(B)** Sample dendrogram and cigarette smoking heatmap (GSE46699).](jcav09p3912g001){#F1}

![**Determination of soft-thresholding power and analysis of hub genes as well as protein-protein interaction network (PPI). (A)** Analysis of the scale-free fit index for various soft-thresholding powers (β). **(B)** Analysis of the mean connectivity for various soft-thresholding powers. **(C)** Histogram of connectivity distribution when β = 11. **(D)** Checking the scale-free topology when β = 11. **(E)** Scatter plot of module eigengenes in lightcyan module. **(F)** PPI network of genes in the lightcyan module.](jcav09p3912g002){#F2}

![**Identify modules associated with the smoking of ccRCC. (A)** Dendrogram of all differentially expressed genes clustered. **(B)** Distribution of average gene significance in the modules associated with smoking of ccRCC. **(C)** The correlation between module eigengenes and the smoking group.](jcav09p3912g003){#F3}

![**Validate the relationship between *TOP2A* and smoking ccRCC samples. (A)** *TOP2A* is significantly overexpressed in the ccRCC according to GEPIA database. **(B)** Linear regression analysis between the expressions of *TOP2A* and smoking group. **(C)** The expression of *TOP2A* is correlated with smoking of ccRCC in GSE46699 (N represents non-smoking patients, S represents smoking patients). **(D)** *TOP2A* expression is correlated with smoking of ccRCC in GSE2109. **(E)** *TOP2A* expression is positive correlation with smoking status in lung adenocarcinoma in GSE10072 (NNS: Normal never smoked, NFS: Normal former smoker, NCS: Normal current smoker, TNS: Tumor never smoked, TFS: Tumor former smoker, TCS: Tumor current smoker). **(F)** qRT-PCR indicates the expression of *TOP2A* is up-regulated in smoking ccRCC tissues. **(G-H)** Kaplan-Meier survival curve downloaded from GEPIA database demonstrate that up-regulation of *TOP2A* have a significantly shorter overall survival time and disease-free survival time. **(I)** Biological processes and **(J)** KEGG pathway enrichment analysis of *TOP2A*.](jcav09p3912g004){#F4}

![**Gene set enrichment analysis (GSEA).** "Viral myocarditis", "Antigen processing and presentation", "Leishmania infection", "Cell cycle", "Autoimmune Thyoid disease", "P53 signaling pathway" were enriched in ccRCC samples with TOP2A highly expressed.](jcav09p3912g005){#F5}

![**Downregulation of *TOP2A* inhibited cell proliferation by triggered cell cycle arrest at G2 phase in ccRCC cells. (A)** The expression of *TOP2A* in transcriptional level (upper picture) and translation level (lower picture) by treating with *siTOP2A-1*, *siTOP2A-2* and *siTOP2A-3* in 786-O cell line. The proliferative capacity was measured by**(B)** MTT assay and **(C)** colony formation assays in 786-O cell line. **(D)** Flow cytometry analysis of *TOP2A* deficiency group and NC group in 786-O cell line. **(E)** Cell cycle related proteins such as Cyclin A1/2 and CDK1/2 were significantly decreased in the 786-O cell line in *TOP2A* knockdown group. **(F)** *TOP2A* deficiency strongly induced phosphorylated p53 in 786-O cell line.](jcav09p3912g006){#F6}

###### 

The description of GSE46699, GSE2109 and GSE10072.

  GEO Dataset   Platform                                      Tumor type   Total samples   Non-smoking samples   Smoking samples   Normal samples   Tumor samples
  ------------- --------------------------------------------- ------------ --------------- --------------------- ----------------- ---------------- ---------------
  GSE46699      Affymetrix Human Genome U133 Plus 2.0 Array   ccRCC        130             84                    46                63               67
  GSE2109       Affymetrix Human Genome U133 Plus 2.0 Array   ccRCC        283             140                   143               \-               283
  GSE10072      Affymetrix Human Genome U133A Array           LUAD         107             31                    76                49               58

###### 

The *P* value of the GSE10072 in Figure [4](#F4){ref-type="fig"}E.

  Smoking status   Mean±SD            Smoking status   Mean±SD       *P*
  ---------------- ------------- ---- ---------------- ------------- -------------
  NNS              5.805±0.469   VS   NFS              6.088±0.555   0.116475331
  NNS              5.805±0.469   VS   NCS              6.251±0.631   0.00052866
  NFS              6.088±0.555   VS   NCS              6.251±0.631   0.034655055
  NNS              5.805±0.469   VS   NFS+NCS          6.642±0.598   0.002130744
                                                                     
  TNS              7.658±1.028   VS   TFS              8.451±0.913   0.076959943
  TNS              7.658±1.028   VS   TCS              9.123±0.851   0.001676115
  TFS              8.451±0.913   VS   TCS              9.123±0.851   0.148011761
  TNS              7.658±1.028   VS   TNS+TCS          8.835±0.939   0.003132606
                                                                     
  NNS+NFS+ NCS     6.054±0.585   VS   TNS+TFS+ TCS     8.510±1.098   1.95169E-25
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